Korea Stock Market Insights

Tag: review

  • Iljin Display Faces Delisting: What Investors Need to Know



    Iljin Display Faces Delisting: What Investors Need to Know 대표 차트 이미지






    What Happened? – Iljin Display Halts Main Operations

    On September 11, 2025, Iljin Display announced a production halt at its Eumseong plant. This constitutes a “major suspension of operations,” triggering a delisting review by the Korea Exchange.

    Why Did This Happen? – Deteriorating Fundamentals

    Iljin Display was already facing a severe financial crisis as of the first half of 2025. Both the AD division (sapphire wafer) and the DS division (touchscreen panel) experienced declining sales and profitability, coupled with increasing debt and lack of liquidity.

    • Sharp decline in sales: Significant drop in AD division sales, decrease in DS division sales
    • Operating loss: Both divisions recorded operating losses
    • Worsening financial health: Increasing debt ratio, declining current ratio

    What Happens Next? – Delisting Possibility and Investment Strategy

    The decision of the Corporate Review Committee will determine Iljin Display’s fate. If designated for review, the likelihood of delisting increases significantly. Even if exempted, share price recovery will be challenging without addressing fundamental issues. Short-term price volatility is inevitable, demanding cautious investor approach.

    What Should Investors Do? – Proceed with Caution, Monitor Closely

    Given the current circumstances, extreme caution is advised for investments in Iljin Display. Monitor the delisting review outcome, the company’s self-rescue plans and management improvement efforts, and macroeconomic changes closely.

    Recommendation: Sell or Hold (Investment decisions should be made carefully at your own discretion and responsibility.)



    Frequently Asked Questions

    Why is Iljin Display facing delisting?

    The production halt at Iljin Display’s Eumseong plant is considered a “major suspension of operations,” which is grounds for a delisting review. The company may be delisted depending on the review’s outcome.

    Should I sell my Iljin Display shares now?

    Iljin Display’s current situation is critical, requiring extreme caution. Experts recommend selling or holding. However, investment decisions should be made carefully at your own discretion and responsibility.

    What is the outlook for Iljin Display?

    The future outlook hinges on the Corporate Review Committee’s decision and the company’s self-rescue efforts. Even if exempted from review, share price recovery may be difficult without resolving fundamental issues. Conversely, inclusion in the review increases the likelihood of delisting.

    What should investors watch out for?

    Investors should closely monitor the Corporate Review Committee’s decision, the resumption of production at the Eumseong plant, the company’s self-rescue plans, and fluctuations in exchange rates and interest rates.









    Iljin Display Faces Delisting: What Investors Need to Know 관련 이미지
    Iljin Display Faces Delisting: What Investors Need to Know 관련 이미지




  • Kodako (046070) Delisting Crisis Deepens: Investor’s Guide



    Kodako (046070) Delisting Crisis Deepens: Investor's Guide 대표 차트 이미지






    What’s Happening with Kodako (046070)?

    The KOSDAQ Market Committee decided on September 5, 2025, to continue the delisting review for Kodako. This is a critical issue that could determine the company’s survival.

    Why is Kodako in this situation?

    Kodako is currently undergoing rehabilitation proceedings and received a “disclaimer of opinion” in its audit report. This raises serious questions about the company’s financial soundness and transparency. High debt ratios and continued losses further darken the company’s prospects for recovery.

    What should investors do?

    • Short-term impact: Increased stock price volatility, potential surge in trading volume and sell-off, deterioration of investor sentiment.
    • Mid- to long-term impact: Possibility of delisting, restrictions on corporate activities, accelerated deterioration of fundamentals.

    Macroeconomic uncertainties could further exacerbate Kodako’s situation.

    Investor Action Plan

    • Suspend investment: New investments should be carefully considered after confirming the review results and the company’s response.
    • Strengthen risk management: Existing investors need to strengthen risk management, considering the possibility of principal loss.
    • Obtain additional information: Carefully analyze all disclosed information, including review results and the company’s position.


    FAQ

    Is Kodako’s delisting confirmed?

    Not yet, but the decision to continue the review increases the likelihood of delisting.

    What are Kodako’s chances of recovery?

    Kodako is undergoing rehabilitation proceedings, but the disclaimer of opinion raises significant uncertainty.

    What should investors do?

    New investments should be put on hold, and existing investors should strengthen risk management. It’s crucial to closely monitor all disclosed information.









    Kodako (046070) Delisting Crisis Deepens: Investor's Guide 관련 이미지




  • NKMAX Trading Halt Extended: Delisting Risk Intensifies? Urgent Investor Check

    NKMAX Trading Halt Extended: Delisting Risk Intensifies? Urgent Investor Check 대표 차트 이미지

    1. What Happened? Analysis of NKMAX’s Trading Halt Extension

    The Korea Exchange announced on September 3, 2025, a 15-business-day extension of the review period for determining whether NKMAX is subject to delisting review, until September 24th. This also means an extension of NKMAX’s trading halt.

    2. Why Did This Happen? Background and Issues

    NKMAX received approval for its rehabilitation plan in June 2025 and has been making efforts to normalize management, including changing its largest shareholder. However, there are still challenges to overcome, such as severe capital impairment and continuous operating losses. These factors influence the decision regarding delisting review.

    • Positive Factors: Achieving rehabilitation milestones, change of largest shareholder, growth potential of the immune cell therapy market
    • Negative Factors: Severe capital impairment, continuous operating losses, delisting uncertainty

    3. What’s Next? Future Outlook and Scenarios

    The extension of the review period can be interpreted as increasing the likelihood of delisting. NKMAX’s stock price is expected to be highly volatile depending on the final decision on September 24th. In the worst case, it could lead to delisting, causing significant losses to investors.

    4. What Should Investors Do? Action Plan

    Currently, investing in NKMAX carries very high risks. It is advisable to hold off on investments and observe the situation until the announcement on September 24th. If you have already invested, you should prepare for the possibility of delisting.

    • Suspend investment and wait
    • Consider the worst-case delisting scenario
    • Strengthen information monitoring

    Frequently Asked Questions

    When will the results of NKMAX’s delisting review be announced?

    It is scheduled to be announced on September 24, 2025.

    What is the probability of NKMAX being delisted?

    While the extension of the review period is interpreted as increasing the likelihood of delisting, nothing is confirmed. We must wait for the announcement on September 24th.

    Should I sell NKMAX stock now?

    Currently, trading is halted, so selling is not possible. The decision to sell should be made after the results are announced on September 24th, when trading resumes. Investment decisions should be made carefully, and consulting with a professional is recommended.

    NKMAX Trading Halt Extended: Delisting Risk Intensifies? Urgent Investor Check 관련 이미지

  • Exion Group Trading Resumes: Rebound or Risk? Investment Strategy Analysis



    Exion Group Trading Resumes: Rebound or Risk? Investment Strategy Analysis 대표 차트 이미지






    What Happened?

    Exion Group’s trading was halted on August 14, 2025, due to reasons related to delisting review. However, with the submission of amended reports on August 29, these reasons were resolved, and trading will resume on September 2.

    Why Did This Happen?

    This was due to the discovery of errors in revenue recognition in the 2025 semi-annual report, necessitating amended disclosures. This process led to revisions in the financial statements, notably a decrease of 66 million won in consolidated net income.

    What Are the Implications?

    • Short-Term Impact: Trading resumption is positive for investor sentiment and liquidity. However, there is a possibility of increased stock price volatility in the initial stages.
    • Long-Term Impact: Enhanced transparency of financial information is positive. However, high debt-to-equity ratio and uncertainties surrounding new businesses remain risk factors.
    • Market Impact: Provides a positive example for similar companies. However, there’s a possibility of increased competition due to business diversification.

    Investor Action Plan

    While the resumption of trading is positive, uncertainties persist regarding Exion Group’s fundamentals. Investors should consider the following:

    • Check the plan to strengthen financial soundness
    • Evaluate the performance and growth potential of new businesses
    • Confirm improvements in internal control systems
    • Review strategies to respond to macroeconomic variables and market volatility

    Investors should make prudent investment decisions by closely monitoring the company’s earnings announcements, progress of new businesses, etc.



    FAQ

    When will Exion Group’s trading resume?

    Trading will resume on September 2, 2025.

    What is the outlook for the stock price after trading resumes?

    High volatility is expected in the short term, and the long-term stock price will depend on improvements in financial soundness and the performance of new businesses.

    What are the key considerations for investors?

    Investments should be made prudently, considering the high debt-to-equity ratio and uncertainties surrounding new businesses. It is crucial to carefully analyze the company’s disclosed information and market conditions.









    Exion Group Trading Resumes: Rebound or Risk? Investment Strategy Analysis 관련 이미지




  • iCure (175250) Trading Halt Extended: Can it Avoid Delisting?

    iCure (175250) Trading Halt Extended: Can it Avoid Delisting? 대표 차트 이미지

    What Happened?

    On August 27, 2025, iCure announced that its delisting review period has been extended to September 17th. This signifies a need for further investigation and the final outcome could lead to continued suspension or resumption of trading.

    Why Did This Happen?

    iCure has been under review for delisting due to past corporate governance issues. Although the company has made efforts to improve governance, the exchange decided further investigation was necessary.

    What’s Next?

    Positive Factors:

    • Improved Financials: Despite a decrease in total assets, iCure shows positive trends with increased current assets, decreased liabilities, and increased equity.
    • Cosmetics Business Growth: The development of MCS Emulsion technology-based products and securing major clients are driving sales growth.
    • Corporate Governance Improvement Efforts: The company is making efforts to improve corporate governance, including clarifying minority shareholder rights and introducing electronic voting.

    Negative Factors:

    • Uncertainty of Delisting Criteria: The lack of clarity in the review criteria makes prediction difficult.
    • Past Governance Issues: Past issues could resurface.

    External Factors:

    • Rising KRW/USD Exchange Rate: This could be positive for exporting companies but may lead to increased import costs.
    • Volatility of International Oil Prices: While there is potential for easing logistics costs, volatility remains high.

    What Should Investors Do?

    • Monitor Information Closely: Investors must diligently check announcements and disclosures regarding the delisting review results.
    • Cautious Investment Approach: Maintaining a conservative investment strategy until the results are announced is recommended.
    • Fundamentals-Based Evaluation: Investors should analyze the company’s fundamentals and make investment decisions regardless of the delisting outcome.

    Frequently Asked Questions

    Will iCure be delisted?

    It’s difficult to predict at this point. The outcome depends on the delisting review results. Positive financial improvements and business growth are positive factors, but past governance issues and the uncertainty of review criteria are negative factors.

    When will the delisting review results be announced?

    The results are expected to be announced by September 17, 2025.

    How should investors respond?

    Maintaining a conservative investment strategy and continuously monitoring relevant information until the results are announced is crucial.

    iCure (175250) Trading Halt Extended: Can it Avoid Delisting? 관련 이미지

  • AccessBio Faces Delisting Threat: Crucial D-Day on September 5th – Investor’s Guide

    What’s Happening? AccessBio’s Delisting Review Imminent

    AccessBio is facing a potential delisting review due to an event that occurred on August 14th. The exact reason remains undisclosed, but market speculation points towards issues related to past corrections in business reports.

    What Happens If the Review Proceeds?

    If AccessBio is deemed subject to review, trading of its stock will be halted, and the company will undergo a review by the Corporate Review Committee. The committee’s decision will determine whether AccessBio remains listed, receives an improvement period, or faces delisting. Delisting can have devastating consequences for investors.

    Why is AccessBio in This Situation?

    AccessBio previously issued corrections to its business reports due to omissions in shareholder meeting minutes. Additionally, the company’s financial health deteriorated in 2023 with declining sales and operating profit. While a recovery is projected for 2024, increasing debt-to-equity ratio remains a concern. The success of AccessBio’s post-pandemic sales strategies is also a crucial factor.

    What Should Investors Do?

    Investors should closely monitor developments until the decision on September 5th. Observe AccessBio’s transparency and communication with the market, and reassess investment strategies based on the review outcome. Considering macroeconomic indicators such as exchange rates, interest rates, and oil prices is also vital. Caution is advised given the high level of uncertainty.

    Q: What are the chances of AccessBio being delisted?

    A: It’s difficult to predict at this stage. The outcome hinges on the September 5th decision and the subsequent review by the Corporate Review Committee.

    Q: Does a delisting review mean immediate delisting?

    A: No. If subject to review, AccessBio will be evaluated by the Corporate Review Committee, which can decide to maintain listing, grant an improvement period, or proceed with delisting.

    Q: Should I sell my AccessBio stock now?

    A: Investment decisions are ultimately personal. However, the current uncertainty surrounding AccessBio necessitates careful consideration.

  • NKMAX: Delisting Crisis? Analysis of Substantive Examination and Investment Strategy

    1. What is NKMAX’s delisting review about?

    NKMAX faces a high probability of being subject to a delisting review due to reasons such as accumulated penalties for inaccurate disclosures. On September 3, 2025, the Korea Exchange will decide whether NKMAX will remain listed. If designated for review, the possibility of delisting must be considered.

    2. Why is NKMAX under review?

    This is due to accumulating 15 or more penalty points for inaccurate disclosures within the past year. This is in accordance with Korea Exchange regulations emphasizing the disclosure obligations of listed companies to protect investors. Stricter criteria apply to companies undergoing rehabilitation proceedings.

    3. How will the review results impact the stock price?

    • If included in the review: A sharp drop in stock price and prolonged trading suspension are highly likely. Investor sentiment may be severely dampened due to delisting concerns.
    • If excluded from the review: Trading resumption and a rebound in stock price can be expected. However, sustained growth is difficult to anticipate without fundamental improvements in the company.

    4. What should investors do?

    Investors should pay close attention to the results of the delisting review to be announced on September 3rd. Short-term investment carries very high risk. From a mid-to-long-term perspective, careful consideration should be given to the implementation of the rehabilitation plan, synergy effects with the new major shareholder, and the development progress of the immunotherapy pipeline. Hasty investment decisions can lead to significant losses, so a cautious approach is necessary.

    Frequently Asked Questions

    Will NKMAX be delisted?

    This will be determined based on the results of the substantive examination on September 3rd. If designated for review, the likelihood of delisting increases.

    Should I buy NKMAX stock now?

    Currently, investing in NKMAX carries very high risk. Prudent investment decisions are necessary.

    What is the future of NKMAX?

    Key factors that will determine the future value of the company include passing the delisting review, successful implementation of the rehabilitation plan, and progress in the development of immunotherapeutic agents.

  • STX Faces Delisting Crisis: Trading Suspension and Investment Strategies

    1. What Happened to STX?

    On July 3, 2025, STX was reported to prosecutors for accounting violations, triggering a delisting review. The Korea Exchange confirmed the review on July 24th and will announce the results (delisting, improvement period, trading suspension, etc.) by August 22nd.

    2. STX’s Current Situation

    As of Q3 2025, STX reported revenue of ₩179.7 billion and a net loss of ₩5.2 billion. Declining revenue and increasing losses point to a severe financial crisis. High debt and continued losses raise doubts about STX’s viability. While there are positives, such as the ‘TrollyGo’ platform launch and increased nuclear component orders, their short-term impact is questionable. PK Valve & Engineering’s low operating rate (38.48%) is another concern.

    3. Delisting Probability

    Considering the accounting violations, continued net losses, and negative market sentiment, the probability of STX’s delisting is high. The current unstable market conditions (US/European interest rate hikes, commodity price fluctuations, geopolitical risks, etc.) also pose challenges for STX.

    4. What Should Investors Do?

    Investors should seriously consider the possibility of delisting. Closely monitoring the Korea Exchange’s review results and any further disclosures is crucial for making informed investment decisions.

    How likely is STX to be delisted?

    Given the accounting violations and continued net losses, the likelihood of delisting is high. However, nothing is certain until the Korea Exchange makes its final decision.

    Should I sell my STX stock now?

    Investment decisions are personal, but STX currently carries significant risk. Consider the possibility of delisting carefully before making any decisions.

    What is the outlook for STX?

    The short-term outlook is very negative. The Korea Exchange’s review results and the success of STX’s financial improvement plan will determine its fate.